& Schweizer, A
Regul Pept 167(23):177184 Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour J-F, Schattenberg JM, Kawaguchi T, Arrese M, Valenti L, Shiha G, Tiribelli C, Yki-Jrvinen H, Fan J-G, Grnbk H, Yilmaz Y, Cortez-Pinto H, Oliveira CP, Bedossa P, Adams LA, Zheng M-H, Fouad Y, Chan W-K, Mendez-Sanchez N, Ahn SH, Castera L, Bugianesi E, Ratziu V, George J (2020) A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
Brighten: Why do you think that these are so effective for your thyroid patients
167 million AFU Bacillus clausii
Experts highlight the need for stronger FDA regulations and market-level change
A Lilly spokesperson told Reuters the company expected the FDA to conduct a fulsome review of the drug and make a science-based decision.